Sentien Biotechnologies Appoints Dr. Pedro Huertas as Chief Medical Officer

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel cell therapies to restore balance to the immune system, today announced the appointment of Pedro Huertas, M.D. Ph.D., as its Chief Medical Officer.  Dr. Huertas will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101.

Dr. Huertas brings nearly 30 years of pharmaceutical industry experience in research and development, medical affairs, and regulatory affairs in therapeutics for human genetic and metabolic diseases.  Prior to joining Sentien, Dr. Huertas was Chief Medical Officer for Eloxx Pharmaceuticals, a company focused on rare and ultra-rare genetic diseases.  His prior experience includes clinically-focused positions with big pharmaceutical (Pfizer, Genzyme), small biotechnology (ExSAR Corporation, Amicus Therapeutics, Novazyme), and cell therapy companies (Ocata, StemCells, Inc.).  Dr. Huertas is a graduate of Stanford University (M.S., Biochemistry), Harvard University (Ph.D., Cell and Developmental Biology), Harvard Medical School (M.D.), and MIT Sloan School of Management (M.S., Management).  He also trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.

Read more here.

Sentien to sponsor and exhibit at the Cellular Therapeutics in Trauma & Critical Care Conference from May 17-19 in San Francisco

Sentien Biotechnologies is a sponsor and exhibitor at the 2017 Cellular Therapeutics & Critical Care Conference being held from May 17-19 in San Francisco.  This is the third in a series of conferences, entitled “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Medicine: Looking towards the Future.”

Sentien Announces Active IND for SBI-101 in Patients with Acute Kidney Injury

At the Stem Cell Summit on 4/7, Sentien CEO Brian Miller announced that the company’s investigational new drug (IND) application for SBI-101 for the treatment of adult patients with acute kidney injury (AKI) is now active.  The IND, which the company has filed in the United States with the Food and Drug Administration, enables Sentien to initiate a multi-center, Phase 1/2 trial to evaluate the administration of SBI-101 in this patient population.  The trial will be the first clinical program for Sentien Biotechnologies.

“This marks a very significant milestone for our company as we move our lead product into the clinic,” said Mr. Miller.  “We are motivated and excited by the opportunity to advance SBI-101 into the clinic to treat patients with severe AKI, which represents a significant unmet medical need.”

SBI-101, Sentien’s investigational product candidate, is a platform treatment modality that combines mesenchymal stromal cells (MSCs) within a blood-filtration device, allowing for controlled, sustained delivery of MSC secreted factors.

The trial will be a randomized, controlled, multi-dose Phase 1/2 study in patients with acute kidney injury receiving continuous renal replacement therapy.  The primary objective of this trial is to evaluate the safety and tolerability of SBI-101 in patients with acute kidney injury.  Endpoints for SBI-101 efficacy will also be evaluated.  Study enrollment is slated to begin in the second quarter of 2017 and is expected to continue into 2018, with an estimated enrollment of 24 patients.

Sentien Biotechnologies, Inc. Announces $12 Million Series A Financing

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced today that it has closed a $12 million Series A investment round. The financing was co-led by Boehringer Ingelheim Venture Fund USA, Inc. (BIVF USA) and BioInnovation Capital, and joined by Chiesi Ventures, MBL Venture Capital Co., Ltd, and Mass Medical Angels. The Series A round will be used to fund initial clinical development of Sentien’s SBI- 101 for the treatment of acute kidney injury (AKI).  Learn more here.



Sentien CEO Brian Miller to Speak at Stem Cell Summit on April 7 in Boston

Sentien Biotechnologies CEO Brian Miller will be a Distinguished Speaker at the Stem Cell Summit to be held in Boston, MA from April 5-7, 2017.  Mr. Miller will address attendees during the Emerging Pipelines session of the Stem Cell Product Development & Commercialization segment of the Summit.  The title of Mr. Miller’s talk is “Developing a Novel Approach to Cell Therapy” during which he will discuss SBI-101, Sentien’s lead product, and its clinical applications.

“The Stem Cell Summit is particularly timely this year as we are in a very exciting time for Sentien,” said Mr. Miller.  “Next month, we will be moving our lead product into the clinic to treat patients with severe AKI, which represents a significant unmet medical need.”

The Summit will cover all areas of stem cell research from bench to bedside, including the biology, medicine, applications, regulations, product development, and the commercialization of stem cells.

Sentien CEO Brian Miller Featured on Front Page of BioWorld™ Today

Sentien Biotechnologies CEO Brian Miller was featured on the front page of BioWorld™ Today on September 15, 2016.  Mr. Miller participated on a Biopharm America panel discussing “How to Value Your Startup” in Boston, MA.  Joining him on the panel were Martin Heidecker, director and investment manager with the Boehringer Ingelheim Venture Fund, Patrik Frei, Founder of CEO of Venture Valuation, and Ryan Muldoon, CEO of PrEP Biopharma.  Read more here: (subscription may be required).

Core Patent Issued in USA

A patent entitled, “Compositions, Methods, and Devices for Treating Liver Disease” (US Patent # 8,172,784 B2) was issued. The invention describes a system comprising a therapeutic bioreactor containing a population of undifferentiated multipotent stromal cells for the treatment of organ injury.